HealthcareServices

CD20 Antibody Market Trends 2025–2029: Forecasts for Key Growth Segments

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The CD20 Antibody Market Over The Five-Year Period 2025–2029?

The cd20 antibody market has experienced significant expansion over recent years. This market is projected to expand from $9.94 billion in 2024 to $10.96 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 10.3%. The historical growth can be attributed to the escalating prevalence of b-cell malignancies, a rise in autoimmune disease incidence, an expanding need for targeted therapies, more biosimilar approvals, higher healthcare spending, advancements in healthcare infrastructure, and heightened understanding of the advantages of immunotherapy.

The cd20 antibody market size is anticipated to experience substantial growth in the upcoming years. This market is projected to reach $16.09 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.1%. Key factors fueling this expansion during the forecast period include the increasing need for advanced cancer immunotherapies, a rise in autoimmune disorder cases, wider adoption of biosimilar CD20 antibodies, broader utility in combination treatments, increased funding for biopharmaceutical research, and a greater understanding of personalized medicine. Significant developments expected in the forecast period encompass the creation of next-generation CD20 antibodies, progress in antibody-drug conjugates, the incorporation of artificial intelligence into antibody design, enhancements in bispecific antibody technology, the emergence of CAR-T cell therapies targeting CD20, the use of nanotechnology for improved delivery, and advancements in high-throughput screening techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21131&type=smp

What Are The Drivers Pushing New Developments In The CD20 Antibody Market?

The increasing occurrence of B-cell malignancies is anticipated to drive the future growth of the CD20 antibody market. B-cell malignancies refer to the rising number of cancer cases affecting B cells, a type of white blood cell involved in immune responses. This trend is linked to several factors, including an aging population, genetic predispositions, environmental exposures, lifestyle choices, advancements in detection, and changes in the immune system. CD20 antibodies, such as rituximab, are utilized to target and remove malignant B-cells in B-cell malignancies like non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby enhancing treatment outcomes. For example, in 2024, a report published by the American College of Cardiology, a US-based nonprofit medical association, estimates that in 2025, approximately 80,350 individuals (45,140 males and 35,210 females), encompassing both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Additionally, around 19,390 people (11,060 males and 8,330 females) are projected to die from this cancer. Therefore, the growing prevalence of B-cell malignancies is stimulating the expansion of the CD-19 antibody market.

What Are The Emerging Segments Gaining Attention In The CD20 Antibody Market?

The cd20 antibodymarket covered in this report is segmented –

1) By Type: Monoclonal Antibody; Polyclonal Antibody

2) By Application: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Western Blot; Immunoprecipitation; Immunofluorescence

3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users

Subsegments:

1) By Monoclonal Antibody: Rituximab; Obinutuzumab; Ofatumumab

2) By Polyclonal Antibody: Conventional Polyclonal Antibodies; Human Polyclonal Antibodies; Recombinant Polyclonal Antibodies

What Key Innovation Trends Are Fueling Advancements In The CD20 Antibody Market?

Leading companies in the CD20 antibody market are focusing on developing technological innovations such as biosimilars to improve treatment accessibility, reduce healthcare costs, and meet the growing demand for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biological medical products that are highly similar to an already approved reference product, showing no clinically significant differences in safety, purity, or efficacy. For instance, in July 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate and stated its intention to work closely with the USFDA to address and resolve all concerns within the stipulated timelines, aiming to make the biosimilar rituximab available to patients in the United States. Rituximab biosimilar operates by targeting the CD20 protein on the surface of B-cells, initiating a response that leads to the destruction of these abnormal or overactive B-cells.

Who Are The Major Companies Operating In The CD20 Antibody Market?

Major companies operating in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, TG Therapeutics Inc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cd20-antibody-global-market-report

Which Region Is Projected To Lead The CD20 Antibody Market During The Forecast Period?

North America was the largest region in the CD20 antibody market in 2024. The regions covered in the CD20 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The CD20 Antibody Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21131&type=smp

Browse Through More Reports Similar to the Global CD20 Antibody Market 2025, By The Business Research Company

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Contract Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Next Generation Antibody Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795